Hot melt emulsification shear method for solid lipid-based suspension: from laboratory-scale to pilot-scale production

Chao Li, Wenqing Xie, Liwen Yuan, Mubbashar Abbas, Dongmei Chen, Shuyu Xie
{"title":"Hot melt emulsification shear method for solid lipid-based suspension: from laboratory-scale to pilot-scale production","authors":"Chao Li, Wenqing Xie, Liwen Yuan, Mubbashar Abbas, Dongmei Chen, Shuyu Xie","doi":"10.1186/s44149-023-00098-4","DOIUrl":null,"url":null,"abstract":"Abstract The clinical application of solid lipid particles (SLPs) is hampered due to the need for advanced nano/micro-suspension production technology. This research aims to establish a pilot-scale production line employing high-speed shears as emulsification equipment. The primary purpose is to manufacture nano/micro-suspensions using solid lipid particles (SLPs). The study also exhaustively introduces and analyzes the regulatory schemes for process parameters and formulations at various stages of production. The process and formulation endured optimization through orthogonal or single-factor tests at various production steps: laboratory research, small-scale trial production, and pilot production. Quality standards for the product were determined, and key parameters were obtained at each stage. The laboratory research demonstrated that the optimal SLPs comprised 15 mL 3% polyvinyl alcohol (PVA) per 1.0 g tilmicosin and 2.5 g carnauba wax (WAX). During small-scale production, modifications were made to the volume of the aqueous phase, emulsifier concentration, and emulsification strength, setting them to 16 mL, 5%, and 2200 r/min, respectively. In the pilot production stage, the shear time was considered optimal at eight min. The impurity, content, polydispersion coefficient (PDI), and size of the pilot product were < 3%, 5%, 0.385 and 2.64 μm, respectively. Among the several parameters studied, heating temperature, drug-lipid ratio, and emulsifier concentration were identified as the main factors affecting product quality, and they were regulated at 100℃, 1:3, and 5%, respectively. A novel hot melt emulsification shear method aided the development of a new solid lipid-based suspension from its preliminary stages in the laboratory to pilot production. This innovation is expected to enhance solid lipid-based suspensions' industrial evolution extensively.","PeriodicalId":69105,"journal":{"name":"动物疾病(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"动物疾病(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s44149-023-00098-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract The clinical application of solid lipid particles (SLPs) is hampered due to the need for advanced nano/micro-suspension production technology. This research aims to establish a pilot-scale production line employing high-speed shears as emulsification equipment. The primary purpose is to manufacture nano/micro-suspensions using solid lipid particles (SLPs). The study also exhaustively introduces and analyzes the regulatory schemes for process parameters and formulations at various stages of production. The process and formulation endured optimization through orthogonal or single-factor tests at various production steps: laboratory research, small-scale trial production, and pilot production. Quality standards for the product were determined, and key parameters were obtained at each stage. The laboratory research demonstrated that the optimal SLPs comprised 15 mL 3% polyvinyl alcohol (PVA) per 1.0 g tilmicosin and 2.5 g carnauba wax (WAX). During small-scale production, modifications were made to the volume of the aqueous phase, emulsifier concentration, and emulsification strength, setting them to 16 mL, 5%, and 2200 r/min, respectively. In the pilot production stage, the shear time was considered optimal at eight min. The impurity, content, polydispersion coefficient (PDI), and size of the pilot product were < 3%, 5%, 0.385 and 2.64 μm, respectively. Among the several parameters studied, heating temperature, drug-lipid ratio, and emulsifier concentration were identified as the main factors affecting product quality, and they were regulated at 100℃, 1:3, and 5%, respectively. A novel hot melt emulsification shear method aided the development of a new solid lipid-based suspension from its preliminary stages in the laboratory to pilot production. This innovation is expected to enhance solid lipid-based suspensions' industrial evolution extensively.
固体脂基悬浮液的热熔乳化剪切法:从实验室规模到中试规模生产
由于需要先进的纳米/微悬浮液生产技术,固体脂质颗粒(SLPs)的临床应用受到阻碍。本研究旨在建立一条以高速剪切机为乳化设备的中试生产线。主要目的是使用固体脂质颗粒(SLPs)制造纳米/微悬浮液。研究还详尽地介绍和分析了不同生产阶段的工艺参数和配方的调节方案。通过实验室研究、小规模试制和中试生产等不同生产步骤的正交或单因素试验,对工艺和配方进行了优化。确定了产品的质量标准,并获得了各阶段的关键参数。实验室研究表明,最佳SLPs为每1.0 g替米考辛15 mL 3%聚乙烯醇(PVA)和2.5 g巴西棕榈蜡(wax)。在小规模生产中,对水相体积、乳化剂浓度和乳化强度进行了修改,分别设置为16 mL、5%和2200 r/min。在中试生产阶段,剪切时间为8 min为最佳。中试产品的杂质、含量、多分散系数(PDI)和粒度为;分别为3%、5%、0.385和2.64 μm。在研究的几个参数中,确定了加热温度、药脂比和乳化剂浓度是影响产品质量的主要因素,并将其分别调节在100℃、1:3和5%。一种新型的热熔乳化剪切方法帮助新型固体脂基悬浮液从实验室的初步阶段发展到中试生产。这一创新有望广泛促进固体脂基悬浮液的工业发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信